Figure 1.
Overall Survival (OS) and Relapse-Free Survival (RFS) in 349 patients with cytogenetically normal acute myeloid leukemia and NPM1 mutation treated in the AMLCG99 study.
(A) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (B) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. (C) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (D) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. Abbreviations: CR, complete remission; FLT3-ITD+, presence of an internal tandem duplication in the fms-related tyrosine 3 gene; FLT3-ITD-, absence of an internal tandem duplication in the fms-related tyrosine 3 gene; NPM1-A, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide TCTG; NPM1-RA, mutation in the nucleophosmin gene other than type A.
Table 1.
Multivariable Cox regression models for OS and RFS in 349 NPM1-mutated patients.
Figure 2.
Overall Survival (OS) and Relapse-Free Survival (RFS) in 349 patients with cytogenetically normal acute myeloid leukemia and NPM1 mutation treated in the AMLCG99 study.
(A) OS in patients with NPM1 type A mutation versus NPM1 type B mutation versus NPM1 type D mutation versus NPM1 type other mutation. (B) RFS in patients with NPM1 type A mutation versus NPM1 type B mutation versus NPM1 type D mutation versus NPM1 type other mutation. Abbreviations: CR, complete remission; FLT3-ITD+, presence of an internal tandem duplication in the fms-related tyrosine 3 gene; FLT3-ITD-, absence of an internal tandem duplication in the fms-related tyrosine 3 gene; NPM1-A, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide TCTG; NPM1-B, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide CATG, NPM1-D, mutation in the nucleophosmin gene consisting of an insertion of the tetranucleotide CCTG, NPM1-other, mutation in the nucleophosmin gene other than NPM1 mutation types A, B, D.